{"id":58217,"date":"2026-04-09T14:50:10","date_gmt":"2026-04-09T14:50:10","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/58217\/"},"modified":"2026-04-09T14:50:10","modified_gmt":"2026-04-09T14:50:10","slug":"jim-cramer-shares-why-novo-nordisk-nvo-might-feel-the-heat-from-eli-lilly","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/58217\/","title":{"rendered":"Jim Cramer Shares Why Novo Nordisk (NVO) Might Feel The Heat From Eli Lilly"},"content":{"rendered":"\n

We just covered<\/p>\n

Jim Cramer Discussed The Iran Ceasefire & Commented On These 19 Stocks<\/a>. Novo Nordisk A\/S (NYSE:NVO) is one of the stocks discussed by Jim Cramer.<\/p>\n

Novo Nordisk A\/S (NYSE:NVO)\u2019s shares are down by 40% over the past year and by 29.6% year-to-date. BMO Capital kept a Market Perform rating and a $45 share price target on the firm on March 30th. The financial firm remained optimistic about the tailwinds from Novo Nordisk A\/S (NYSE:NVO)\u2019s Wegovy weight loss pill, but added that the firm nevertheless faced industry-wide risks. On March 18th, Bernstein initiated coverage of the stock to set a $175 share price target and an Underperform rating. Bernstein commented that Novo Nordisk A\/S (NYSE:NVO) was facing a \u201cbare\u201d catalyst path and cautioned that the firm\u2019s weight loss drugs could struggle in the US due to lower volumes and price deflation. After the weight loss pill secured the FDA\u2019s approval earlier this year, Cramer pointed out that it might experience hesitance from doctors who are unwilling to switch drugs for patients. In this appearance, he discussed Novo Nordisk A\/S (NYSE:NVO)\u2019s claim that its weight loss pill was better than Lilly\u2019s product:<\/p>\n

\u201cLook, if you wanted a pill and you wanted to be able to take it when you want, and you don\u2019t have to worry about taking it with the food and stuff, that\u2019s a, Lilly\u2019s got that going. Remember, the main thing that Lilly has got going is they\u2019re not gonna run out, that they have spent a fortune [on manufacturing].\u201d<\/p>\n

\"Jim Jim Cramer Shares Why Novo Nordisk (NVO) Might Feel The Heat From Eli Lilly <\/p>\n

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the\u00a0best short-term AI stock<\/a>.<\/p>\n

READ NEXT:\u00a033 Stocks That Should Double in 3 Years<\/a> and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy<\/a>.<\/p>\n

Disclosure: None. Follow Insider Monkey on Google News<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"We just covered Jim Cramer Discussed The Iran Ceasefire & Commented On These 19 Stocks. Novo Nordisk A\/S…\n","protected":false},"author":2,"featured_media":58218,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[2961,272,32095,277],"class_list":{"0":"post-58217","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-jim-cramer","9":"tag-novo-nordisk","10":"tag-share-price-target","11":"tag-weight-loss-drugs"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116375311101293809","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/58217","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=58217"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/58217\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/58218"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=58217"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=58217"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=58217"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}